COMP <GO>
INCR vs ZYBT // NET PROFIT MARGIN
Intercure Ltd. (NASDAQ) VS. Zhengye Biotechnology Holding Limited (Class A) (NASDAQ) • 15-METRIC TALLY: INCR 0
— ZYBT 2
■ METRIC PARITY
LAST: $4.02 (-0.74%) • MKT CAP: $60.8M
net-margins
—
LAST: $1.34 (+0.75%) • MKT CAP: $63.0M
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INCR VS. ZYBT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INCR | ZYBT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 20.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -22.30% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.61% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -34.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.90 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.1 | 45.1 | -13.00 | ZYBT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $60.8M | $63.0M | -$2.3M | ZYBT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INCR REV | ZYBT REV | INCR GROSS % | ZYBT GROSS % | INCR FCF | ZYBT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $16.6M | — | 20.5% | — | $1.8M |
| FY 2024 | — | $25.5M | — | 49.0% | — | $3.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INCR // BETA —
ZYBT // BETA —